Upper GI

Staging

8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice
Thomas W. Rice, Deepa T. Patil, Eugene H. Blackstone
Ann Cardiothorac Surg 2017;6(2):119-130. doi: 10.21037/acs.2017.03.14

Evaluation of the updated TNM 8 staging system for oesophageal and gastro-oesophageal junction cancers and its implications on clinical practice.

Gastric Cancer Staging AJCC eighth edition
Duncan McLeod
Australasian Gastrointestinal Pathology Society. Available from http://www.agps.org.au/resources/AGM_Stuff/2017_AGM/Update%20on%20Gastric%20AJCC%208th%20Ed.pdf. Accessed 11/8/2020

A presentation explaining the TNM 8 staging system for gastric cancer and its implications on clinical practice

View Online

Management- Radical

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
P. van Hagen, M.C.C.M. Hulshof, J.J.B. van Lanschot, E.W. Steyerberg, M.I. van Berge Henegouwen, B.P.L. Wijnhoven, D.J. Richel, G.A.P. Nieuwenhuijzen, G.A.P. Hospers, J.J. Bonenkamp, M.A. Cuesta, R.J.B. Blaisse, O.R.C. Busch, F.J.W. ten Kate, G.-J. Creemers, C.J.A. Punt, J.T.M. Plukker, H.M.W. Verheul, E.J. Spillenaar Bilgen, H. van Dekken, M.J.C. van der Sangen, T. Rozema, K. Biermann, J.C. Beukema, A.H.M. Piet, C.M. van Rij, J.G. Reinders, H.W. Tilanus, and A. van der Gaast,
N Engl J Med 2012;366:2074-84.

Seminal CROSS study evaluating neoadjuvant chemoradiotherapy versus surgery alone for oesophageal and gastro-oesophageal junction cancers

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Salah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, Thorsten O Goetze, Johannes Meiler, Stefan Kasper, Hans-Georg Kopp, Frank Mayer, Georg Martin Haag, Kim Luley , Udo Lindig, Wolff Schmiegel, Michael Pohl, Jan Stoehlmacher, Gunnar Folprecht, Stephan Probst, Nicole Prasnikar, Wolfgang Fischbach, Rolf Mahlberg, Jörg Trojan, Michael Koenigsmann, Uwe M Martens, Peter Thuss-Patience, Matthias Egger, Andreas Block, Volker Heinemann, Gerald Illerhaus, Markus Moehler, Michael Schenk, Frank Kullmann, Dirk M Behringer, Michael Heike, Daniel Pink, Christian Teschendorf, Carmen Löhr, Helga Bernhard, Gunter Schuch, Volker Rethwisch, Ludwig Fischer von Weikersthal, Jörg T Hartmann, Michael Kneba, Severin Daum, Karsten Schulmann, Jörg Weniger, Sebastian Belle, Timo Gaiser, Fuat S Oduncu, Martina Güntner, Wael Hozaeel, Alexander Reichart, Elke Jäger, Thomas Kraus, Stefan Mönig, Wolf O Bechstein, Martin Schuler, Harald Schmalenberg, Ralf D Hofheinz,
Lancet 2019; 393: 1948–57

FLOT versus ECX as perioperative chemotherapy for gastric and gastro-oesophageal adenocarcinoma

Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
David Cunningham, M.D., William H. Allum, M.D., Sally P. Stenning, M.Sc., Jeremy N. Thompson, M.Chir., Cornelis J.H. Van de Velde, M.D., Ph.D., Marianne Nicolson, M.D., J. Howard Scarffe, M.D., Fiona J. Lofts, Ph.D., Stephen J. Falk, M.D., Timothy J. Iveson, M.D., David B. Smith, M.D., Ruth E. Langley, M.D., Ph.D., Monica Verma, M.Sc., Simon Weeden, M.Sc., and Yu Jo Chua, M.B., B.S.,
N Engl J Med 2006;355:11-20.

Seminal MAGIC study of perioperative ECF chemotherapy versus surgery alone for gastric/gastro-oesopheal/oesophageal adenocarcinoma

Management- Palliative

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
David Cunningham, M.D., F.R.C.P., Naureen Starling, M.R.C.P., Sheela Rao, M.R.C.P., Timothy Iveson, M.D., F.R.C.P., Marianne Nicolson, M.D., F.R.C.P., Fareeda Coxon, F.R.C.P., Gary Middleton, M.D., F.R.C.P., Francis Daniel, M.B., Ch.B., R.C.S.I., F.F.R., Jacqueline Oates, and Andrew Richard Norman, Ph.D.,
N Engl J Med 2008;358:36-46.

ECF vs ECX vs EOF vs EOX as first line treatment for advanced/metastatic gastro-oesophageal cancer

OPTIMIZING CHEMOTHERAPY FOR FRAIL AND/OR ELDERLY PATIENTS WITH ADVANCED GASTROESOPHAGEAL CANCER (AGOAC): THE GO2 PHASE III TRIAL
D. E. Swinson, P. Hall, S. Lord, H. Marshall, S. Ruddock, C. Allmark, D. Cairns, J. Waters, J. Wadsley, S. Falk, R. Roy, M. Joseph, J. Nicoll, K. Vellios Kamposioras, T. Tillett, S. Cummins, S. Grumett, Z. Stokes, T. Waddell, A. Chatterjee, A. Garcia, M. Khan R. Petty, M. Seymour
Journal of Geriatric Oncology, 2019-11-01, Volume 10, Issue 6, Pages S8-S8,

Abstract from the GO2 study evaluating dosing of CAPOX chemotherapy for advanced/metastatic oesophagogastric cancer in the frail and/or elderly